In [1]:
import pandas as pd
pd.set_option("display.max_columns", None)
import plotly.io as pio
import plotly.express as px # Plotting
pio.renderers.default = 'notebook'
pd.options.plotting.backend = "plotly"
from tqdm import tqdm
from pprint import pprint
tqdm.pandas()
df = pd.read_csv("applications.csv")
df.Community_URL__c = "https://connect.pharmac.govt.nz" + df.Community_URL__c
df
Out[1]:
| Id | Name | Applications__c | Brand_Name__c | Chemical_Name__c | Applicants__c | Funding_requested_for__c | Stage__c | Pharmaceutical__c | Community_URL__c | Therapeutic_group__c | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | a0ROZ000009J5Ev2AK | 15-valent pneumococcal conjugate vaccine (PCV15) | A-04423 | VAXNEUVANCE. | 15-valent pneumococcal conjugate vaccine (PCV15) | MERCK SHARP & DOHME (NEW ZEALAND) LIMITED | Prevention of invasive pneumococcal disease | Decision | 15-valent pneumococcal conjugate vaccine (PCV1... | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
| 1 | a0ROZ000004CX2l2AG | Adjuvanted inactivated quadrivalent influenza ... | A-03341 | FLUAD® QUAD | Adjuvanted inactivated quadrivalent influenza ... | Seqirus | influenza vaccination for people aged 65 years... | Decision | Adjuvanted inactivated quadrivalent influenza ... | https://connect.pharmac.govt.nz/apptracker/s/a... | National Immunisation Schedule |
| 2 | a0ROZ00000Cn1xE2AR | Adjuvanted inactivated trivalent influenza vac... | A-00724 | Fluad | Adjuvanted inactivated trivalent influenza vac... | Seqirus | Influenza vaccine for people 65 years of age a... | Options Compared | Adjuvanted inactivated trivalent influenza vac... | https://connect.pharmac.govt.nz/apptracker/s/a... | National Immunisation Schedule |
| 3 | a0R2P000000gVYDUA2 | Bevacizumab and Human Papillomavirus (HPV) vac... | A-00655 | NaN | Bevacizumab and Human Papillomavirus (HPV) vac... | PHARMAC Initiated | Recurrent respiratory papillomatosis | Decision | Bevacizumab and Human Papillomavirus (HPV) vac... | https://connect.pharmac.govt.nz/apptracker/s/a... | Respiratory System and Allergies |
| 4 | a0R2P000000LmcWUAS | Diphtheria and tetanus vaccine | A-00221 | NaN | Diphtheria and tetanus vaccine | PHARMAC Initiated | Widening of access | Decision | Diphtheria and tetanus vaccine | https://connect.pharmac.govt.nz/apptracker/s/a... | National Immunisation Schedule |
| ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| 2010 | a0ROZ00000083aG2AQ | AEON Sodium Chloride 5 Percent | A-04432 | AEON | AEON Sodium Chloride 5 Percent | MEDIX 21 LIMITED | Corneal oedema relief | Seeking Clinical Advice | AEON Sodium Chloride 5 Percent (AEON) | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
| 2011 | a0ROZ00000DqVYD2A3 | Pegunigalsidase alfa-iwxj | A-05325 | ELFABRIO | Pegunigalsidase alfa-iwxj | CHIESI NEW ZEALAND LIMITED | Fabry Disease | Options Compared | Pegunigalsidase alfa-iwxj (ELFABRIO) | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
| 2012 | a0ROZ000003nufF2AQ | Elemental Food (Elemental Gold) | A-04296 | It is not a pharmaceutical. The brand name is ... | Elemental Food (Elemental Gold) | ENDOTHERAPEUTICS NZ LIMITED | Currently funded indications | Seeking Clinical Advice | Elemental Food (Elemental Gold) (It is not a p... | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
| 2013 | a0ROZ00000AQkoE2AT | SARS-CoV-2 rS (Omicron XBB.1.5) | A-04785 | NUVAXOVID XBB.1.5 | SARS-CoV-2 rS (Omicron XBB.1.5) | BIOCELECT NEW ZEALAND LIMITED | prevention of COVID-19 | Options Compared | SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB... | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
| 2014 | a0ROZ0000070NGj2AM | Elasomeran, Elasomeran and Davesomeran, Anduso... | A-04863 | SPIKEVAX | Elasomeran, Elasomeran and Davesomeran, Anduso... | Moderna Australia Pty Ltd | active immunisation to prevent coronavirus dis... | Under Assessment | Elasomeran, Elasomeran and Davesomeran, Anduso... | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN |
2015 rows × 11 columns
In [2]:
events = pd.read_json(f"applications/{df['Id'].iloc[0]}.json").dropna()
events
Out[2]:
| text | position | name | last | events | dateString | collapsed | checked | |
|---|---|---|---|---|---|---|---|---|
| 0 | <p>New funding applications are referred to on... | 0 | Application Received | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Aug 2022 | False | True |
| 1 | <p>Pharmac is identifying and gathering inform... | 1 | Seeking Clinical Advice | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Sep 2022 | False | True |
| 2 | <p>Following Clinical Advice, Pharmac staff co... | 2 | Under Assessment | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Mar 2023 | False | True |
| 3 | <p>Pharmac staff uses a prioritisation process... | 3 | Options Compared | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Jun 2024 | False | True |
| 4 | <p>Pharmac is consulting on a proposal to eith... | 4 | Under Consultation | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Oct 2024 | False | True |
| 5 | <p>Following the consultation process, Pharmac... | 5 | Reviewing Consultation Feedback | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Nov 2024 | False | True |
| 6 | <p>We refer to our decisions about whether and... | 6 | Decision | True | [{'Summary': {'s': None, 'fs': None, 'change':... | Jun 2025 | False | True |
In [3]:
days_until_each_stage = pd.to_datetime(events.set_index("name").dateString.dropna(), errors="coerce").diff().dropna()
days_until_each_stage.index = "Days until " + days_until_each_stage.index
days_until_each_stage
/tmp/ipykernel_997791/985086398.py:1: UserWarning: Could not infer format, so each element will be parsed individually, falling back to `dateutil`. To ensure parsing is consistent and as-expected, please specify a format.
Out[3]:
name Days until Seeking Clinical Advice 31 days Days until Under Assessment 181 days Days until Options Compared 458 days Days until Under Consultation 122 days Days until Reviewing Consultation Feedback 31 days Days until Decision 212 days Name: dateString, dtype: timedelta64[ns]
In [4]:
pprint(events.events.iloc[-1])
[{'Event_Description': {'change': None,
'fs': 'The funding application has been declined.',
's': 'The funding application has been declined.'},
'Formatted_Date': {'change': None, 'fs': 'Jun 2025', 's': 'Jun 2025'},
'Links': {'change': None,
'fs': '<p><a '
'href="https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines" '
'target="_blank">Notification of the decision</a></p>',
's': '<p><a '
'href="https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines" '
'target="_blank">Notification of the decision</a></p>'},
'Outcome': {'change': None, 'fs': None, 's': None},
'PTAC_Comments': {'change': None, 'fs': None, 's': None},
'Published_Application': {'change': None, 'fs': None, 's': None},
'Published_Discussion': {'change': None, 'fs': None, 's': None},
'Published_Recommendation': {'change': None, 'fs': None, 's': None},
'Summary': {'change': None, 'fs': None, 's': None},
'change': None,
'e': {'Event_Date__c': '2025-06-17',
'Event_Description__c': 'The funding application has been declined.',
'Formatted_Date__c': 'Jun 2025',
'Id': 'a0POZ00000Mc77I2AR',
'Links__c': '<p><a '
'href="https://www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/2025-06-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines" '
'target="_blank">Notification of the decision</a></p>',
'Stage__c': 'Decision',
'Status_History__c': 'a13OZ00000OhRFMYA3',
'attributes': {'type': 'Application_Event__c',
'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Mc77I2AR'}}}]
In [5]:
rows = []
for i, row in tqdm(df.iterrows(), total=len(df)):
events = pd.read_json(f"applications/{row.Id}.json").dropna()
start = pd.to_datetime(events.events.iloc[0][0]["e"]["Event_Date__c"])
end = pd.to_datetime(events.events.iloc[-1][0]["e"]["Event_Date__c"])
delta = end - start
row = row.to_dict()
row["Application Received date"] = start
row["Last Update date"] = end
row["Days elapsed between application and last update"] = delta.days
days_until_each_stage = pd.to_datetime(events.set_index("name").dateString.dropna(), errors="coerce", format="%b %Y").diff().dropna()
days_until_each_stage.index = "Days until " + days_until_each_stage.index
row.update(days_until_each_stage)
for stage in events.events:
stage_events = []
for event in stage:
try:
stage_events.append(event["e"]["Event_Date__c"] + ":" + event["e"]["Event_Description__c"])
except KeyError:
print(event)
row[event["e"]["Stage__c"] + " dates"] = "\r\n".join(stage_events)
rows.append(row)
df = pd.DataFrame(rows)
df.sort_values("Application Received date", inplace=True)
df
16%|█▌ | 320/2015 [00:01<00:05, 291.03it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2012', 'fs': 'Jul 2012', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000vYNw2AM'}, 'Id': 'a0POZ000000vYNw2AM', 'Event_Date__c': '2012-07-01', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2012', 'Status_History__c': 'a132P000000Aq3yQAC'}, 'change': None}
42%|████▏ | 851/2015 [00:03<00:04, 274.40it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec', 'fs': 'Dec', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyAAUA0'}, 'Id': 'a0P2P000007JyAAUA0', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Dec', 'Status_History__c': 'a132P000000Clc2QAC'}, 'change': None}
55%|█████▌ | 1111/2015 [00:03<00:03, 274.33it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000012oZf2AI'}, 'Id': 'a0POZ0000012oZf2AI', 'Event_Date__c': '2022-08-01', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000DwrGQAS'}, 'change': None}
72%|███████▏ | 1448/2015 [00:05<00:02, 267.97it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC's relevant decision-making framework for these recommendations.</p>', 'fs': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC's relevant decision-making framework for these recommendations.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic & Clinical Pharmacology & Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p<0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p<0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'fs': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic & Clinical Pharmacology & Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p<0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p<0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'fs': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'fs': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9b2AB'}, 'Id': 'a0POZ00000Ogl9b2AB', 'Event_Date__c': '2016-11-03', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'Formatted_Date__c': 'Nov 2016', 'Published_Recommendation__c': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC's relevant decision-making framework for these recommendations.</p>', 'Published_Application__c': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'Published_Discussion__c': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic & Clinical Pharmacology & Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p<0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p<0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'Status_History__c': 'a132P000000ArCwQAK'}, 'change': None}
83%|████████▎ | 1674/2015 [00:06<00:01, 280.56it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2017', 'fs': 'Oct 2017', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000032tQR2AY'}, 'Id': 'a0POZ0000032tQR2AY', 'Event_Date__c': '2017-10-12', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Oct 2017', 'Status_History__c': 'a132P000000ArLkQAK'}, 'change': None}
90%|█████████ | 1820/2015 [00:06<00:00, 283.52it/s]
{'Summary': {'s': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'fs': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'fs': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2025', 'fs': 'Jul 2025', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000VK8PX2A1'}, 'Id': 'a0POZ00000VK8PX2A1', 'Event_Date__c': '2025-07-22', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://www.pharmac.govt.nz/assets/Provisional-Summary-of-recommendations-from-June-2025-Rare-Disorders-Committee-meeting.pdf</p>', 'Summary__c': '<p>A summary of provisional recommendations from the June 10 2025 Rare Disorders Committee meeting has been published. Within the context of treatments for rare disorders, Garadacimab was recommended with a <strong>High Priority</strong> for the treatment of hereditary angioedema, subject to Special Authority criteria.</p>', 'Formatted_Date__c': 'Jul 2025', 'Status_History__c': 'a13OZ00000Qk4L5YAJ'}, 'change': None}
95%|█████████▍| 1909/2015 [00:06<00:00, 289.57it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2012', 'fs': 'Dec 2012', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztraUAA'}, 'Id': 'a0P2P000002ztraUAA', 'Event_Date__c': '2012-12-01', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2012', 'Status_History__c': 'a132P000000AqG0QAK'}, 'change': None}
99%|█████████▉| 1996/2015 [00:07<00:00, 272.15it/s]
{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2013', 'fs': 'Jun 2013', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000F3gLZ2AZ'}, 'Id': 'a0POZ00000F3gLZ2AZ', 'Event_Date__c': '2013-06-01', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2013', 'Status_History__c': 'a132P000000AqQ1QAK'}, 'change': None}
100%|██████████| 2015/2015 [00:07<00:00, 278.58it/s]
Out[5]:
| Id | Name | Applications__c | Brand_Name__c | Chemical_Name__c | Applicants__c | Funding_requested_for__c | Stage__c | Pharmaceutical__c | Community_URL__c | Therapeutic_group__c | Application Received date | Last Update date | Days elapsed between application and last update | Days until Seeking Clinical Advice | Days until Under Assessment | Days until Options Compared | Days until Under Consultation | Days until Reviewing Consultation Feedback | Days until Decision | Application Received dates | Seeking Clinical Advice dates | Under Assessment dates | Options Compared dates | Under Consultation dates | Reviewing Consultation Feedback dates | Decision dates | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 688 | a0R2P000000LmkWUAS | Risperidone tablets | A-01127 | Risperdal | Risperidone tablets | Janssen | Schizophrenia | Decision | Risperidone tablets (Risperdal) | https://connect.pharmac.govt.nz/apptracker/s/a... | Nervous System | 1994-04-01 | 1995-10-01 | 548 | 0 days | 244 days | -91 days | NaT | NaT | 395 days | 1994-04-01:Application received | 1994-04-01:Clinical advice required\r\n1994-06... | 1994-12-01:Working to compare options\r\n1995-... | 1994-09-01:The relative ranking of the pharmac... | NaN | NaN | 1995-10-01:The funding application has been Ap... |
| 584 | a0R2P000000LmjmUAC | Gabapentin | A-01197 | Neurontin | Gabapentin | Parke Davis | Partial seizures in patients who have not achi... | Decision | Gabapentin (Neurontin) | https://connect.pharmac.govt.nz/apptracker/s/a... | Nervous System | 1994-08-01 | 2001-03-01 | 2404 | 184 days | 28 days | 61 days | 2072 days | NaT | 59 days | 1994-08-01:Application received | 1995-02-01:Clinical advice required\r\n1995-03... | 1995-03-01:Working to compare options | 1995-05-01:The relative ranking of the pharmac... | 2001-01-01:Public consultation for this applic... | NaN | 2001-03-01:The funding application has been Ap... |
| 982 | a0R2P000000LmThUAK | Somatropin - Growth Hormone | A-01165 | Genotropin | Somatropin - Growth Hormone | Clinician | Adult and adolescent patients with growth ho... | Decision | Somatropin - Growth Hormone (Genotropin) | https://connect.pharmac.govt.nz/apptracker/s/a... | Hormone Preparations - Systemic Excluding Cont... | 1995-09-01 | 2005-09-01 | 3653 | 0 days | 427 days | -366 days | 5083 days | NaT | -1491 days | 1995-09-01:Application received | 1995-09-01:Clinical advice required\r\n1995-11... | 1996-11-01:Working to compare options | 1995-11-01:The relative ranking of the pharmac... | 2009-10-01:Public consultation for this applic... | NaN | 2005-09-01:The funding application has been Ap... |
| 593 | a0R2P000000Lmo2UAC | Interferon beta-1-beta | A-01183 | Betaferon | Interferon beta-1-beta | Bayer | Relapsing remitting multiple sclerosis | Decision | Interferon beta-1-beta (Betaferon) | https://connect.pharmac.govt.nz/apptracker/s/a... | Nervous System | 1996-01-01 | 1999-07-01 | 1277 | 0 days | NaT | 1216 days | 0 days | NaT | 61 days | 1996-01-01:Application received | 1996-01-01:Clinical advice required\r\n1996-03... | NaN | 1999-05-01:The relative ranking of the pharmac... | 1999-05-01:Public consultation for this applic... | NaN | 1999-07-01:The funding application has been Ap... |
| 1407 | a0R2P000000LmqWUAS | Anastrozole | A-01169 | Arimidex | Anastrozole | AstraZeneca | Third line treatment of advanced breast cancer | Decision | Anastrozole (Arimidex) | https://connect.pharmac.govt.nz/apptracker/s/a... | Oncology Agents and Immunosuppressants | 1997-02-01 | 1998-12-01 | 668 | 0 days | 89 days | 518 days | 0 days | NaT | 61 days | 1997-02-01:Application received | 1997-02-01:Clinical advice required\r\n1997-05... | 1997-05-01:Working to compare options | 1998-10-01:The relative ranking of the pharmac... | 1998-10-01:Public consultation for this applic... | NaN | 1998-12-01:The funding application has been Ap... |
| ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| 1282 | a0ROZ00000Dms532AB | Riociguat | A-05544 | ADEMPAS | Riociguat | Clinician | Chronic Thromboembolic Pulmonary Hypertension ... | Seeking Clinical Advice | Riociguat (ADEMPAS) | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN | 2025-10-28 | 2026-02-02 | 97 | 123 days | NaT | NaT | NaT | NaT | NaT | 2025-10-28:Application received | 2026-02-02:Clinical advice required | NaN | NaN | NaN | NaN | NaN |
| 1770 | a0ROZ00000DL1uT2AT | Mepolizumab | A-05540 | Nucala | Mepolizumab | GLAXOSMITHKLINE NZ LIMITED | Inadequately controlled chronic obstructive pu... | Seeking Clinical Advice | Mepolizumab (Nucala) | https://connect.pharmac.govt.nz/apptracker/s/a... | Respiratory System and Allergies | 2025-10-31 | 2026-01-09 | 70 | 92 days | NaT | NaT | NaT | NaT | NaT | 2025-10-31:Application received | 2026-01-09:Clinical advice required | NaN | NaN | NaN | NaN | NaN |
| 1841 | a0ROZ00000DGeA52AL | Upadacitinib | A-05543 | Rinvoq | Upadacitinib | ABBVIE LIMITED | Giant cell ateritis (GCA), glucocorticoid tape... | Seeking Clinical Advice | Upadacitinib (Rinvoq) | https://connect.pharmac.govt.nz/apptracker/s/a... | Musculoskeletal System | 2025-10-31 | 2026-01-05 | 66 | 92 days | NaT | NaT | NaT | NaT | NaT | 2025-10-31:Application received | 2026-01-05:Clinical advice required | NaN | NaN | NaN | NaN | NaN |
| 1919 | a0ROZ00000DKizt2AD | pembrolizumab | A-05472 | KEYTRUDA | pembrolizumab | MERCK SHARP & DOHME (NEW ZEALAND) LIMITED | Squamous Cell Carcinoma of the Head and Neck, ... | Seeking Clinical Advice | pembrolizumab (KEYTRUDA) | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN | 2025-12-19 | 2026-01-09 | 21 | 31 days | NaT | NaT | NaT | NaT | NaT | 2025-12-19:Application received | 2026-01-09:Clinical advice required | NaN | NaN | NaN | NaN | NaN |
| 1126 | a0ROZ00000DoZ9Z2AV | Emicizumab | A-05466 | Hemlibra | Emicizumab | Clinician | Haemophilia A, moderate severity, severe bleed... | Seeking Clinical Advice | Emicizumab (Hemlibra) | https://connect.pharmac.govt.nz/apptracker/s/a... | NaN | 2026-01-14 | 2026-02-03 | 20 | 31 days | NaT | NaT | NaT | NaT | NaT | 2026-01-14:Application received | 2026-02-03:Clinical advice required | NaN | NaN | NaN | NaN | NaN |
2015 rows × 27 columns
In [6]:
df.describe()
Out[6]:
| Application Received date | Last Update date | Days elapsed between application and last update | Days until Seeking Clinical Advice | Days until Under Assessment | Days until Options Compared | Days until Under Consultation | Days until Reviewing Consultation Feedback | Days until Decision | |
|---|---|---|---|---|---|---|---|---|---|
| count | 2015 | 2015 | 2015.000000 | 1944 | 1549 | 1551 | 1398 | 1120 | 1480 |
| mean | 2014-05-26 13:35:24.267990016 | 2018-03-16 14:57:35.285359872 | 1390.057072 | 140 days 12:11:06.666666666 | 424 days 09:19:38.308586184 | 296 days 00:48:16.711798840 | 783 days 18:53:02.832618024 | 66 days 14:38:08.571428571 | 156 days 07:05:11.351351352 |
| min | 1994-04-01 00:00:00 | 1995-10-01 00:00:00 | -94.000000 | -2557 days +00:00:00 | -2162 days +00:00:00 | -6087 days +00:00:00 | -6270 days +00:00:00 | -671 days +00:00:00 | -7215 days +00:00:00 |
| 25% | 2011-01-01 00:00:00 | 2013-04-24 00:00:00 | 485.000000 | 0 days 00:00:00 | 28 days 00:00:00 | 0 days 00:00:00 | 31 days 00:00:00 | 28 days 00:00:00 | 31 days 00:00:00 |
| 50% | 2013-12-02 00:00:00 | 2019-07-11 00:00:00 | 866.000000 | 61 days 00:00:00 | 213 days 00:00:00 | 122 days 00:00:00 | 334 days 00:00:00 | 30 days 00:00:00 | 61 days 00:00:00 |
| 75% | 2019-04-07 12:00:00 | 2024-03-29 00:00:00 | 1844.500000 | 181 days 00:00:00 | 427 days 00:00:00 | 396 days 00:00:00 | 1126 days 00:00:00 | 31 days 00:00:00 | 151 days 00:00:00 |
| max | 2026-01-14 00:00:00 | 2026-02-11 00:00:00 | 9922.000000 | 4626 days 00:00:00 | 7946 days 00:00:00 | 5875 days 00:00:00 | 7975 days 00:00:00 | 7184 days 00:00:00 | 6515 days 00:00:00 |
| std | NaN | NaN | 1372.478161 | 381 days 02:19:44.749732920 | 836 days 23:06:13.989561008 | 818 days 06:10:48.919041072 | 1243 days 22:09:53.186913056 | 431 days 09:08:11.626936856 | 681 days 08:41:04.928734328 |
In [7]:
df.Therapeutic_group__c.value_counts().head(20)
Out[7]:
Therapeutic_group__c Oncology Agents and Immunosuppressants 431 Nervous System 250 Alimentary Tract and Metabolism 181 Infections - Agents for Systemic Use 162 Blood and Blood Forming Organs 100 Dermatologicals 98 Cardiovascular System 92 Special Foods 89 Respiratory System and Allergies 85 National Immunisation Schedule 84 Musculoskeletal System 76 Hormone Preparations - Systemic Excluding Contraceptive Hormones 53 Genito-Urinary System 51 Sensory Organs 50 Various 15 Extemporaneous Compounds 8 Name: count, dtype: int64
In [8]:
df.Applicants__c.value_counts().head(20)
Out[8]:
Applicants__c Clinician 495 PHARMAC Initiated 385 Subcommittee recommendation 57 Roche 47 Consumer 45 Novartis 42 Merck Sharp & Dohme 40 Janssen 38 NPPA 32 AstraZeneca 31 Nutricia 29 Pharmac Initiated 24 GLAXOSMITHKLINE NZ LIMITED 23 Pfizer 23 ROCHE PRODUCTS (NEW ZEALAND) LIMITED 22 GlaxoSmithKline 21 ABBVIE LIMITED 20 Gilead Sciences 20 Boehringer Ingelheim 19 ASTRAZENECA LIMITED 18 Name: count, dtype: int64
In [9]:
df.Stage__c.value_counts().plot.bar()
In [10]:
df.to_excel("Pharmac applications.xlsx", index=False)
In [11]:
df["Last Update date"].groupby(df["Last Update date"].dt.to_period("M").astype(str)).count().plot(title="Number of applications last updated per month").data[0]
Out[11]:
Scatter({
'hovertemplate': 'variable=Last Update date<br>index=%{x}<br>value=%{y}<extra></extra>',
'legendgroup': 'Last Update date',
'line': {'color': '#636efa', 'dash': 'solid'},
'marker': {'symbol': 'circle'},
'mode': 'lines',
'name': 'Last Update date',
'orientation': 'v',
'showlegend': True,
'x': array(['1995-10', '1998-06', '1998-11', ..., '2025-12', '2026-01', '2026-02'],
dtype=object),
'xaxis': 'x',
'y': array([ 1, 1, 1, ..., 24, 28, 14]),
'yaxis': 'y'
})
In [12]:
fig = df["Application Received date"].groupby(df["Application Received date"].dt.to_period("M").astype(str)).count().plot(title="Number of applications received per month")
fig.add_trace(df["Last Update date"].groupby(df["Last Update date"].dt.to_period("M").astype(str)).count().plot(title="Number of applications last updated per month").update_traces(line_color='magenta').data[0])
In [13]:
df["Application Received date"].value_counts()
Out[13]:
Application Received date
2011-01-01 276
2012-05-01 27
2014-08-01 21
2013-11-01 20
2010-03-01 18
...
2016-11-08 1
2016-11-07 1
2016-11-01 1
2016-10-18 1
2026-01-14 1
Name: count, Length: 790, dtype: int64
In [14]:
df["Decision dates"].dropna().str.replace("Declined", "declined").str.replace("Approved", "approved").str.split("\r\n").apply(lambda x: x[-1].split(":")[1]).value_counts()
Out[14]:
Decision dates The funding application has been approved. 871 The funding application has been declined. 595 The funding application has been . 11 The funding application has been out of scope. 3 The funding application is closed. 1 Name: count, dtype: int64
In [15]:
all_events = []
for i, row in tqdm(df.iterrows(), total=len(df)):
events = pd.read_json(f"applications/{row.Id}.json").dropna()
events["id"] = row.Id
all_events.append(events)
events = pd.concat(all_events).reset_index()
events
100%|██████████| 2015/2015 [00:04<00:00, 450.46it/s]
Out[15]:
| index | text | position | name | last | events | dateString | collapsed | checked | id | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | <p>New funding applications are referred to on... | 0 | Application Received | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Apr 1994 | False | True | a0R2P000000LmkWUAS |
| 1 | 1 | <p>Pharmac is identifying and gathering inform... | 1 | Seeking Clinical Advice | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Apr 1994 | False | True | a0R2P000000LmkWUAS |
| 2 | 2 | <p>Following Clinical Advice, Pharmac staff co... | 2 | Under Assessment | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Dec 1994 | False | True | a0R2P000000LmkWUAS |
| 3 | 3 | <p>Pharmac staff uses a prioritisation process... | 3 | Options Compared | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Sep 1994 | False | True | a0R2P000000LmkWUAS |
| 4 | 6 | <p>We refer to our decisions about whether and... | 6 | Decision | True | [{'Summary': {'s': None, 'fs': None, 'change':... | Oct 1995 | False | True | a0R2P000000LmkWUAS |
| ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| 11054 | 1 | <p>Pharmac is identifying and gathering inform... | 1 | Seeking Clinical Advice | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Jan 2026 | False | True | a0ROZ00000DGeA52AL |
| 11055 | 0 | <p>New funding applications are referred to on... | 0 | Application Received | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Dec 2025 | False | True | a0ROZ00000DKizt2AD |
| 11056 | 1 | <p>Pharmac is identifying and gathering inform... | 1 | Seeking Clinical Advice | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Jan 2026 | False | True | a0ROZ00000DKizt2AD |
| 11057 | 0 | <p>New funding applications are referred to on... | 0 | Application Received | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Jan 2026 | False | True | a0ROZ00000DoZ9Z2AV |
| 11058 | 1 | <p>Pharmac is identifying and gathering inform... | 1 | Seeking Clinical Advice | False | [{'Summary': {'s': None, 'fs': None, 'change':... | Feb 2026 | False | True | a0ROZ00000DoZ9Z2AV |
11059 rows × 10 columns
In [16]:
events["date"] = pd.to_datetime(events.dateString, errors="coerce")
events["month"] = events.date.dt.to_period("M")
events["month"]
/tmp/ipykernel_997791/3089976863.py:1: UserWarning: Could not infer format, so each element will be parsed individually, falling back to `dateutil`. To ensure parsing is consistent and as-expected, please specify a format.
Out[16]:
0 1994-04
1 1994-04
2 1994-12
3 1994-09
4 1995-10
...
11054 2026-01
11055 2025-12
11056 2026-01
11057 2026-01
11058 2026-02
Name: month, Length: 11059, dtype: period[M]
In [17]:
events.name.update(events[events.name == "Decision"].events.apply(lambda e: "Approved" if "approved" in e[0]["e"]["Event_Description__c"].lower() else "Declined"))
events.name.value_counts()
/tmp/ipykernel_997791/2827480615.py:1: FutureWarning:
A value is trying to be set on a copy of a DataFrame or Series through chained assignment using an inplace method.
The behavior will change in pandas 3.0. This inplace method will never work because the intermediate object on which we are setting values always behaves as a copy.
For example, when doing 'df[col].method(value, inplace=True)', try using 'df.method({col: value}, inplace=True)' or df[col] = df[col].method(value) instead, to perform the operation inplace on the original object.
Out[17]:
name Application Received 2014 Seeking Clinical Advice 1945 Options Compared 1551 Under Assessment 1549 Under Consultation 1398 Reviewing Consultation Feedback 1121 Approved 871 Declined 610 Name: count, dtype: int64
In [20]:
by_month = []
changing_by_month = []
for month in pd.date_range(events.date.min(), events.date.max(), freq="ME"):
counts = events[events.month <= month.to_period("M")].groupby("id").last().name.value_counts()
by_month.append(counts)
counts = events[events.month == month.to_period("M")].groupby("id").last().name.value_counts()
changing_by_month.append(counts)
by_month = pd.DataFrame(by_month, index=pd.date_range(events.date.min(), events.date.max(), freq="ME").to_period("M").astype(str))
by_month.plot(title="Number of Pharmac applications in each stage by month").show()
by_month.plot.bar(title="Number of Pharmac applications in each stage by month").show()
changing_by_month = pd.DataFrame(changing_by_month, index=pd.date_range(events.date.min(), events.date.max(), freq="ME").to_period("M").astype(str))
changing_by_month.plot.bar(title="Number of Pharmac applications changing to each stage by month").show()
In [21]:
ids = df.Id[df.Therapeutic_group__c == "Oncology Agents and Immunosuppressants"]
by_month = []
changing_by_month = []
for month in pd.date_range(events.date.min(), events.date.max(), freq="ME"):
counts = events[(events.month <= month.to_period("M")) & (events.id.isin(ids))].groupby("id").last().name.value_counts()
by_month.append(counts)
counts = events[(events.month == month.to_period("M")) & (events.id.isin(ids))].groupby("id").last().name.value_counts()
changing_by_month.append(counts)
by_month = pd.DataFrame(by_month, index=pd.date_range(events.date.min(), events.date.max(), freq="ME").to_period("M").astype(str))
by_month.plot(title="Number of Oncology Agents and Immunosuppressants Pharmac applications in each stage by month").show()
changing_by_month = pd.DataFrame(changing_by_month, index=pd.date_range(events.date.min(), events.date.max(), freq="ME").to_period("M").astype(str))
changing_by_month.plot.bar(title="Number of Oncology Agents and Immunosuppressants Pharmac applications changing to each stage by month").show()